Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Effect of pituitary adenylate cyclase-activating polypeptide-27 on cerebral hemodynamics in healthy volunteers: A 3T MRI study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Procholecystokinin expression and processing in cardiac myocytes

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Serum proatrial natriuretic peptide concentrations during oral glucose-induced acute hyperinsulinemia in lean and obese men

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH2

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Gluco-metabolic effects of pharmacotherapy-induced modulation of bile acid physiology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Effect of the incretin hormones on the endocrine pancreas in end-stage renal disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. N-acyl taurines are endogenous lipid messengers that improve glucose homeostasis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Accumulating evidence suggests that glucose-dependent insulinotropic polypeptide (GIP) in addition to its involvement in type 2 diabetic pathophysiology may be involved in the development of obesity and the pathogenesis of cardiovascular disease. In this review, we outline recent preclinical and clinical cardiovascular-related discoveries about GIP. These include chronotropic and blood pressure-lowering effects of GIP. Furthermore, GIP has been suggested to control vasodilation via secretion of nitric oxide, and vascular leukocyte adhesion and inflammation via expression and secretion of endothelin 1. Also, GIP seems to regulate circulating lipids via effects on adipose tissue uptake and metabolism of lipids. Lastly, we discuss how dysmetabolic conditions such as obesity and type 2 diabetes may shift the actions of GIP in an atherogenic direction, and we provide a perspective on the therapeutic potential of GIP receptor agonism and antagonism in cardiovascular diseases. We conclude that GIP actions may have implications for the development of cardiovascular disease, but also that the potential of GIP-based drugs for the treatment of cardiovascular disease currently is uncertain.

OriginalsprogEngelsk
TidsskriftPeptides
ISSN0196-9781
DOI
StatusE-pub ahead of print - 2 nov. 2019

ID: 58311047